HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Combination chemotherapy and high-dose cyclophosphamide intensification for poor prognosis breast cancer. A Southwest Oncology Group Study.

Abstract
Thirty-seven patients with poor prognosis, metastatic breast cancer were treated with 5-fluorouracil, vinblastine, and Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH) (FUVA) induction chemotherapy. All 26 patients (74%) with responsive or stable disease after induction chemotherapy received intensification with high-dose cyclophosphamide (120 mg/kg). Continued responders received additional FUVA as consolidation. The response rate to induction therapy was 54% (with complete response [CR] in 11%). With intensification, three patients (11%) showed improved response (partial response [PR] in one, PR to complete response [CR] in two); however, six patients (23%) progressed within 2 months of cyclophosphamide intensification, three within 1 month. The overall response rate to all three phases of the study was 69%, with CR in 23%. The median survival of all patients entered in this study was 15 months. For cyclophosphamide intensification, major toxicity consisted of leukopenia with fever requiring broad-spectrum antibiotics in 27%. The authors conclude that a single cycle of high-dose cyclophosphamide intensification in metastatic breast cancer does not result in significantly improved responses or prolonged survival.
AuthorsG K Ellis, S Green, S Schulman, B L Tranum, R S Goldberg, R B Livingston
JournalCancer (Cancer) Vol. 64 Issue 12 Pg. 2409-15 (Dec 15 1989) ISSN: 0008-543X [Print] UNITED STATES
PMID2684382 (Publication Type: Clinical Trial, Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Vinblastine
  • Doxorubicin
  • Cyclophosphamide
  • Fluorouracil
Topics
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Bone Neoplasms (secondary)
  • Brain Neoplasms (prevention & control)
  • Breast Neoplasms (drug therapy, mortality, pathology)
  • Clinical Trials as Topic
  • Cyclophosphamide (administration & dosage, therapeutic use)
  • Doxorubicin (administration & dosage)
  • Drug Administration Schedule
  • Fluorouracil (administration & dosage)
  • Humans
  • Neoplasm Recurrence, Local
  • Prognosis
  • Vinblastine (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: